Mechanism

Nicotinamide mononucleotide (NMN) is a NAD+ precursor. In preclinical research, supplying NMN is associated with raising NAD+ levels and supporting NAD+-dependent processes; the extent and clinical relevance in humans are still being studied.

Research summary

Preclinical studies suggest metabolic effects, and some small human trials have examined tolerability and biomarkers. Clinical outcome evidence is still developing, and its regulatory status as a supplement has been subject to change in some jurisdictions. It is not an approved drug for specific indications.

Reported side effects

Small trials have generally reported good tolerability, but long-term human safety data are limited.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

NMN human tolerability and biomarker studies · peer-reviewed clinical studies (2021)search PubMed for NMN human trial
NAD+ precursor review · peer-reviewed review article (2020)class context; clinical outcomes still developing

TrackPep on seurantasovellus. Se tallentaa tekemäsi kirjaukset eikä koskaan suosittele tai laske määriä.